60
Participants
Start Date
May 10, 2024
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2027
Stereotactic body radiotherapy (SBRT)
SBRT 40 gray (Gy) over 5 fractions
Zimberelimab
240 mg intravenously (IV)
Quemliclustat
100 mg IV
Etrumadenant
150 mg orally
Modified FOLFIRINOX
"* Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)"
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
Northwell Health R.J. Zuckerberg Cancer Center, Lake Success
RECRUITING
University of Pennsylvania, Abramson Cancer Center, Philadelphia
RECRUITING
UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Medical College of Wisconsin, Milwaukee
Collaborators (1)
Arcus Biosciences, Inc.
INDUSTRY
Gulam Manji
OTHER